Voyageur Pharmaceuticals Stock Performance
| VYYRF Stock | USD 0.10 0.00 0.00% |
Voyageur Pharmaceuticals holds a performance score of 8 on a scale of zero to a hundred. The entity has a beta of -79.69, which indicates a somewhat significant risk relative to the market. As returns on the market increase, returns on owning Voyageur Pharmaceuticals are expected to decrease by larger amounts. On the other hand, during market turmoil, Voyageur Pharmaceuticals is expected to outperform it. Use Voyageur Pharmaceuticals market risk adjusted performance, information ratio, as well as the relationship between the Information Ratio and kurtosis , to analyze future returns on Voyageur Pharmaceuticals.
Risk-Adjusted Performance
Fair
Weak | Strong |
Compared to the overall equity markets, risk-adjusted returns on investments in Voyageur Pharmaceuticals are ranked lower than 8 (%) of all global equities and portfolios over the last 90 days. Despite nearly fragile basic indicators, Voyageur Pharmaceuticals reported solid returns over the last few months and may actually be approaching a breakup point. ...more
| Begin Period Cash Flow | 2967.00 | |
| Total Cashflows From Investing Activities | -432.1 K |
Voyageur |
Voyageur Pharmaceuticals Relative Risk vs. Return Landscape
If you would invest 12.00 in Voyageur Pharmaceuticals on September 28, 2025 and sell it today you would lose (2.00) from holding Voyageur Pharmaceuticals or give up 16.67% of portfolio value over 90 days. Voyageur Pharmaceuticals is currently producing 14.0698% returns and takes up 124.8416% volatility of returns over 90 trading days. Put another way, most equities are less risky on the basis of their return distribution than Voyageur, and majority of traded equity instruments are likely to generate higher returns over the next 90 trading days. Expected Return |
| Risk |
Voyageur Pharmaceuticals Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Voyageur Pharmaceuticals' investment risk. Standard deviation is the most common way to measure market volatility of pink sheets, such as Voyageur Pharmaceuticals, and traders can use it to determine the average amount a Voyageur Pharmaceuticals' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.1127
| Best Portfolio | Best Equity | VYYRF | ||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns |
Based on monthly moving average Voyageur Pharmaceuticals is performing at about 8% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Voyageur Pharmaceuticals by adding it to a well-diversified portfolio.
Voyageur Pharmaceuticals Fundamentals Growth
Voyageur Pink Sheet prices reflect investors' perceptions of the future prospects and financial health of Voyageur Pharmaceuticals, and Voyageur Pharmaceuticals fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Voyageur Pink Sheet performance.
| Return On Equity | -0.77 | |||
| Return On Asset | -0.38 | |||
| Current Valuation | 5.74 M | |||
| Shares Outstanding | 132.7 M | |||
| Price To Book | 4.11 X | |||
| EBITDA | (2.05 M) | |||
| Cash And Equivalents | 247.78 K | |||
| Total Debt | 25.52 K | |||
| Debt To Equity | 0.03 % | |||
| Book Value Per Share | 0.02 X | |||
| Cash Flow From Operations | (1.65 M) | |||
| Earnings Per Share | (0.02) X | |||
| Total Asset | 2.57 M | |||
About Voyageur Pharmaceuticals Performance
By analyzing Voyageur Pharmaceuticals' fundamental ratios, stakeholders can gain valuable insights into Voyageur Pharmaceuticals' financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if Voyageur Pharmaceuticals has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Voyageur Pharmaceuticals has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
Voyageur Pharmaceuticals Ltd. focuses on the development of active pharmaceutical ingredients minerals. Voyageur Pharmaceuticals Ltd. is headquartered in Calgary, Canada. Voyageur Minerals operates under Drug ManufacturersSpecialty Generic classification in the United States and is traded on OTC Exchange.Things to note about Voyageur Pharmaceuticals performance evaluation
Checking the ongoing alerts about Voyageur Pharmaceuticals for important developments is a great way to find new opportunities for your next move. Pink Sheet alerts and notifications screener for Voyageur Pharmaceuticals help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Voyageur Pharmaceuticals is way too risky over 90 days horizon | |
| Voyageur Pharmaceuticals has some characteristics of a very speculative penny stock | |
| Voyageur Pharmaceuticals appears to be risky and price may revert if volatility continues | |
| Voyageur Pharmaceuticals has high likelihood to experience some financial distress in the next 2 years | |
| Voyageur Pharmaceuticals has accumulated 25.52 K in total debt with debt to equity ratio (D/E) of 0.03, which may suggest the company is not taking enough advantage from borrowing. Voyageur Pharmaceuticals has a current ratio of 0.33, indicating that it has a negative working capital and may not be able to pay financial obligations in time and when they become due. Debt can assist Voyageur Pharmaceuticals until it has trouble settling it off, either with new capital or with free cash flow. So, Voyageur Pharmaceuticals' shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Voyageur Pharmaceuticals sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Voyageur to invest in growth at high rates of return. When we think about Voyageur Pharmaceuticals' use of debt, we should always consider it together with cash and equity. | |
| Net Loss for the year was (2.05 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Voyageur Pharmaceuticals has accumulated about 247.78 K in cash with (1.65 M) of positive cash flow from operations. | |
| Roughly 14.0% of Voyageur Pharmaceuticals outstanding shares are owned by insiders |
- Analyzing Voyageur Pharmaceuticals' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Voyageur Pharmaceuticals' stock is overvalued or undervalued compared to its peers.
- Examining Voyageur Pharmaceuticals' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Voyageur Pharmaceuticals' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Voyageur Pharmaceuticals' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Voyageur Pharmaceuticals' pink sheet. These opinions can provide insight into Voyageur Pharmaceuticals' potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for Voyageur Pink Sheet analysis
When running Voyageur Pharmaceuticals' price analysis, check to measure Voyageur Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Voyageur Pharmaceuticals is operating at the current time. Most of Voyageur Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Voyageur Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Voyageur Pharmaceuticals' price. Additionally, you may evaluate how the addition of Voyageur Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
| Portfolio Dashboard Portfolio dashboard that provides centralized access to all your investments | |
| Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope | |
| Bonds Directory Find actively traded corporate debentures issued by US companies | |
| Idea Breakdown Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes | |
| Headlines Timeline Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity |